Skip to content

The Atlas of Anti-Cancer Drug Nephrotoxicity

How anticancer drugs injure the kidney.

A citation-grounded onconephrology reference that connects 292 agents — chemotherapy, targeted therapy, immunotherapy — by the toxic ties they share, from cisplatin to the 2026 frontier and MGRS.

292 agents · 14 signatures · 1,642 citations · updated November 2026

Every claim tied to a primary source.

§ 01The toxic ties

Agents that injure the kidney the same way

Every agent is wired to each injury it can cause. Chemically unrelated drugs that share a signature pull toward the same hub — drag a node, or open the full network.

Open full network
Figure 1 · Toxic-ties network — agents clustered by shared injury signature

§ 02Why it matters

Kidney injury is a common complication of cancer therapy

Onconephrology sits where two epidemics meet. Every figure below links to its primary source.

Cited epidemiology of drug-induced kidney injury in cancer
IncidenceClinical finding
27%

of cancer patients develop AKI within 5 years

5-year cumulative incidence of acute kidney injury after a cancer diagnosis (1-year: 17.5%).

Christiansen et al., Eur J Intern Med 2011 · PMID 21767759
53%

carry hidden kidney impairment at diagnosis

Abnormal renal function by aMDRD in solid-tumor patients, yet only 7.2% of the cohort had an elevated serum creatinine (IRMA study).

Launay-Vacher et al., Cancer 2007 · PMID 17634949
4.7×

higher odds of death with in-hospital AKI

Cancer inpatients who develop AKI face nearly fivefold mortality, +100% length of stay.

Salahudeen et al., CJASN 2013 · PMID 23243268
~1 in 3

adults develop acute kidney injury after cisplatin

31.5% of 821 adults had AKI (a creatinine rise of more than 25%) within 30 days of the first cycle, in a cohort of patients who survived at least 5 years.

Latcha et al., CJASN 2016 · PMID 27073199

Onconephrology. Onconephrology is the nephrology subspecialty at the bidirectional intersection of cancer and the kidney — the nephrotoxicity of anticancer therapy, AKI and CKD in cancer patients, electrolyte disorders, tumor lysis syndrome, paraneoplastic glomerular disease and drug dosing in renal impairment. The field coalesced around 2010–2014, with the ASN onconephrology forum established in 2011. Read the field primer

§ 03Deep profiles

Start with the foundational agents

All 292 agents carry full, citation-grounded profiles — mechanism, incidence, prevention, management, dose adjustment, clinical pearls, and a real-world FAERS signal where the data exists.

All 292

Cisplatin

Platinol · Platinum agent

Profile

Proximal tubular ATN + magnesium wasting; the archetype.

ATNLYTEPRE+3 more
Severe

Gemcitabine

Gemzar · Nucleoside analog

Profile

Dose-cumulative thrombotic microangiopathy.

TMAHTNGLOM+1 more
Severe

Checkpoint inhibitors (pembrolizumab · nivolumab · ipilimumab)

Immune checkpoint inhibitor

Profile

Acute interstitial nephritis with long latency.

AINGLOMLYTE
Moderate

§ 04Deep dives

The syndromes, told in full

All deep dives
Anti-angiogenics & the glomerular endothelium

VEGF-inhibitor TMA

Starve a tumor of its blood supply and you also cut the survival signal podocytes whisper to the glomerular endothelium next door — the capillary tuft answers with thrombi, protein spilling into the urine, and a blood pressure that will not come down.

7 landmark studies
Platinum & the proximal tubule

Cisplatin ATN & hypomagnesemia

The drug that cures testicular cancer poisons its own portal of entry — pumped into the kidney's S3 tubule by OCT2, cisplatin necroses the proximal tubule and, downstream, silences the distal magnesium channel, leaving patients wasting magnesium long after the last dose.

7 landmark studies
Anti-EGFR antibodies & the distal tubule

EGFR-inhibitor hypomagnesemia

By occupying the EGF receptor that keeps the TRPM6 channel trafficked to the apical membrane of the distal tubule, cetuximab and panitumumab convert the kidney into a magnesium sieve — an on-target, designed-in toxicity that deepens the longer the drug keeps working.

7 landmark studies
Oxazaphosphorine alkylators & the proximal tubule

Ifosfamide Fanconi

Mesna guards the bladder, but nothing guards the proximal tubule — ifosfamide's chloroacetaldehyde metabolite is made inside the tubular cell itself, draining its energy and its reabsorptive machinery until phosphate, glucose, bicarbonate, and amino acids leak into the urine.

4 landmark studies

Updates to the atlas

New agents are discovered from the PubMed literature and reviewed before they appear, with an optional email notice whenever the atlas is updated.

Built on deep research across PubMed and current nephrology literature. Educational reference — not medical advice.